Innovotech Inc. (TSXV: IOT, OTCQB: IOTCF) announced that its common shares have begun trading on the OTCQB Market in the United States, providing U.S. investors with easier access to the diversified life sciences technology company. The company's shares continue to trade on the TSX Venture Exchange under the symbol IOT.
“Listing on the OTCQB allows us to more effectively engage with U.S. investors as we build a larger, more diversified life sciences platform,” said Craig Milne, Chief Executive Officer of Innovotech Inc.
The listing follows a strong 2025 performance, during which Innovotech reported significant revenue growth driven by organic expansion and the full-year contribution from the acquisition of Keystone Labs Inc., completed in November 2024. The company delivered consistent revenues across all quarters, reflecting improved scale and operational execution. The integration of Keystone expanded Innovotech's analytical chemistry and testing capabilities and strengthened its Canadian customer base.
Subsequent to year-end, Innovotech amalgamated its operating entities into a single, integrated laboratory platform. The company also strengthened its balance sheet through warrant exercises and a convertible debenture issuance, providing capital for equipment purchases, operational expansion, and strategic initiatives. Investments in laboratory infrastructure removed capacity bottlenecks and expanded technical capabilities with advanced analytical and microbiology equipment.
Innovotech differentiates itself through expertise in antimicrobial testing and biofilm-related research, supported by accredited quality systems. The company often engages in technically challenging projects requiring reproducibility and regulatory awareness, fostering long-term customer relationships and higher-value contract research. In addition to services, Innovotech manufactures laboratory consumables, including its MBEC Assay® platform used globally in biofilm and antimicrobial research. The company also maintains an active R&D program to expand assay offerings and advance proprietary technologies like its InnovoSIL™ antimicrobial silver platform.
Looking ahead, Innovotech is focused on organic growth, service expansion, and disciplined execution of strategic priorities. The company is evaluating acquisition opportunities and continues to invest in infrastructure, people, and systems to support scale. Following the OTCQB listing, Innovotech is expanding investor outreach efforts in the United States.
“We are building Innovotech deliberately,” added Dr. Milne. “Our focus is on long-term value creation through operational excellence, differentiated capabilities, and disciplined growth.”
Innovotech operates through ISO-certified and GMP-accredited laboratories, supporting clients across multiple sectors and geographies. More information is available at https://www.innovotech.ca.
